UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

Journal of clinical oncology, 2013-12, Vol.31 (35), p.4400-4406

2013

Volltextzugriff (PDF)

The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations

Nutrition in Clinical Practice, 2005-08, Vol.20 (4), p.369-376

2005

Volltextzugriff (PDF)

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Haematologica (Roma), 2016-07, Vol.101 (7), p.e295-e298

2016

Volltextzugriff (PDF)

Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung

Journal of thoracic oncology, 2012-10, Vol.7 (10), p.1618-1621

2012

Volltextzugriff (PDF)

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Advances in therapy, 2013-10, Vol.30 (10), p.870-884

2013

Volltextzugriff (PDF)

Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies

Leukemia & lymphoma, 2024-04, Vol.65 (4), p.503-510

2024

Volltextzugriff (PDF)

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.1095-1102

2019

Volltextzugriff (PDF)

Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options

Cancer management and research, 2015-01, Vol.7 (default), p.37-46

Harb, Wael A

2015

Volltextzugriff (PDF)

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies

Targeted oncology, 2021-07, Vol.16 (4), p.461-469

2021

Volltextzugriff (PDF)

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

Annals of hematology, 2014, Vol.93 (1), p.89-98

2014

Volltextzugriff (PDF)

Oncology clinical trial termination trends: Analysis across the prior 20 years

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13602-e13602

2022

Volltextzugriff (PDF)

Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9100-9100

2021

Volltextzugriff (PDF)

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.101-101

2019

Volltextzugriff (PDF)

Abstract CT213: NEON-1: a first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT213-CT213

2021

Volltextzugriff (PDF)

First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2547-2547

2021

Volltextzugriff (PDF)

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9110-9110

2021

Volltextzugriff (PDF)

Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2521-2521

2021

Volltextzugriff (PDF)

Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9546-9546

2020

Volltextzugriff (PDF)

Real-time identification of tumor lesions and response to vintafolide treatment

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5533-5533

2014

Volltextzugriff (PDF)

Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS9102-TPS9102

2016

Volltextzugriff (PDF)

A phase 1 dose-escalation study of the folic acid-tubulysin small molecule drug conjugate (SMDC) folate-tubulysin EC1456 in advanced cancer patients

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2585-2585

2016

Volltextzugriff (PDF)

A phase I open label study evaluating VT1021 in patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS3158-TPS3158

2019

Volltextzugriff (PDF)

Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2576-2576

2017

Volltextzugriff (PDF)

1 – 25 von 192

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(183)
Mit Volltextzugriff
(178)

Publikationsform

Sprache

Englisch
(192)

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(72)
Humans
(41)
Cardiac & Cardiovascular Systems
(29)
Cardiovascular System & Cardiology
(29)
Female
(28)
Aged
(24)
Male
(24)
Middle Aged
(24)
Oncology
(24)
Adult
(17)
Cardiology
(17)
Aged, 80 And Over
(16)
Radiology, Nuclear Medicine & Medical Imaging
(15)
Treatment Outcome
(13)
Medicine
(11)
Mortality
(11)
Hematology
(10)
Medicine & Public Health
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

Oncology clinical trial termination trends: Analysis across the prior 20 years

Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC)

Abstract CT213: NEON-1: a first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update

Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab

Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab

Real-time identification of tumor lesions and response to vintafolide treatment

Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial

A phase 1 dose-escalation study of the folic acid-tubulysin small molecule drug conjugate (SMDC) folate-tubulysin EC1456 in advanced cancer patients

A phase I open label study evaluating VT1021 in patients with advanced solid tumors

Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers

Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456

Suchergebnisse filtern